A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Clinical trial NCT06472076 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06472076
Sponsor: GlaxoSmithKline
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2024-06-10
Primary completion: 2026-06-30
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.